For example, when BRAF and MEK inhibitors are used together in BRAF-mutant melanoma or when EGFR and HER2 inhibitors are combined in HER2-positive breast cancer, there are better treatment responses and a slower development of resistance [55,56]. Here, ERBB2 is linked to melanoma.